May
7
2025
Upcoming webinar

Spot-on, standard-free AAV titer and characterization with Stunner

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Spot-on, standard-free AAV titer and characterization with Stunner

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Problem

Adding up AAV capsid titers has to start somewhere – and leaning on standards isn’t always an option. Differences in aggregation or serotype between off-the-shelf capsid standards and the AAV you’re testing could throw off standards curves used in classic quantitative ELISAs.

Solution

Getting to answers from another direction with light scattering makes for a standard-free, unbiased way to check out everything is titering at the right level. From 2 microliters of sample and in 2 minutes, Stunner reads titer from first principles light scattering without any sample processing, reagents, or standards – and helps you keep an eye on aggregation and the total amount of DNA and protein present.

Proof

In this webinar, we’ll check out the secrets behind how Stunner delivers titer values without any help from standard curves. We’ll also show how Stunner fits into your downstream AAV characterization or sample QC to spot when samples have gone sour with aggregation and stop unfit samples from eating up resource-intensive troubleshooting.

  • Understand how light scattering can connect to AAV titer
  • See how the strengths of a biophysical method can complement sequence-specific PCR or ELISA methods
  • Understand the risk aggregation poses and where it may strike
Kevin Lance
Kevin Lance
Director, Product Management at Unchained Labs

Kevin Lance directs product management and covers the Stunner portfolio globally at Unchained Labs. His expertise includes biophysical characterization of viral vectors, lipid nanoparticles, proteins, and nucleic acids. Prior to Unchained Labs, his research experience covered the fields of sustained antibody delivery and nanotechnology. He earned his Ph.D. in Bioengineering from the joint UC Berkeley – UCSF Bioengineering Graduate Program.